Vaccine Antigen | Age at Initial Vaccination: | Booster Interval: | Additional Comments: |
| Under 12 weeks | Over 12 weeks | | |
Panleukopenia
parenteral MLV
intranasal MLV | vaccinate at initial visit and then every 3-4 weeks until >12 weeks | 1 dose | 1 year later then every 3 years | Highly recommended. Not for use in pregnant females or kittens <4 weeks or immune compromised |
Panleukopenia
killed vaccine | vaccinate at initial visit and then every 3-4 weeks until >12 weeks | 2 doses
3-4 weeks apart | 1 year later then every 3 years | Highly recommended |
FHV-1/FCV 2
parenteral MLV
intranasal MLV | vaccinate at initial visit and then every 3-4 weeks until >12 weeks | 1 dose | 1 year later then every 3 years | Highly recommended |
FHV-1/FCV
killed vaccine | vaccinate at initial visit and then every 3-4 weeks until >12 weeks | 2 doses
3-4 weeks apart | 1 year later then every 3 years | Highly recommended |
Rabies
killed vaccine | | 1 dose | 1 year later then every 3 years | Highly recommended for all cats |
Chlamydia
avirulent live vaccine | 1 dose | 1 dose | 1 year later then annually | Recommended for use in cats at high risk of exposure |
Chlamydia
killed vaccine | 2 doses
3-4 weeks apart | 2 doses
3-4 weeks apart | 1 year later then annually | Recommended for use in cats at high risk of exposure |
FIP
intranasal MLV | | 2 doses
3-4 weeks apart not earlier than 16 weeks | 1 year later then annually | It is reasonable to vaccinate cats at risk of exposure to other cats with known or clinically suspected exposure to feline corona virus |
FeLV
killed vaccine | 2 doses
3-4 weeks apart;
1st dose > 8 weeks;
2nd dose >12 weeks | 2 doses
3-4 weeks apart | 1 year later then annually | Follow testing recommendations as published in the AAFP/AFM Recommendation for Feline Retrovirus Testing. Recommended for use in cats with high risk of exposure. |
M. Canis
killed vaccine | | Prevention:
3 doses; 2 weeks between 1st and 2nd then 3rd dose 3 weeks after 2nd dose.
Treatment:
3 doses; 2 weeks between 1st and 2nd then 3rd dose 3 weeks after 2nd dose. 3rd dose is at DVM discretion.
| Guidelines for long term use or booster intervals not available | Not recommended for routine use. Insufficient data to evaluate use in prevention or elimination of M. Canis infection. |
